Disclsoure of Outcome of Board Meeting pursuant to Regulation 30 of SEBI (LODR), 2015 for declaration of Unaudited Financial Results (Standalone and Consolidated) for the quarter and half year ended September 30, 2026

Mangalam Drugs and Organics Limited % | MANCALAM | Regd. Office }}lfpam Building, 3rd Floor, 239 P. D'Mello Road, Near G. P, O. Mumbai - 400 001. nh__4& ®91-22-62616200 / 63/0 87087 @ 91-22-62619090 » CIN : L24230MH1972PLC116413 Accredited REF: MDOL/CS-SE/2026- 27/041 5t November, 2026 Listing Department Listing Department National Stock Exchange of India Limited BSE Ltd 15t Floor, New Trade Wing, “Exchange Plaza”, 5 Floor, Phiroze Jeejeebhoy Towers, Plot No. C-1, Block G, Dalal Street, Fort, Bandra - Kurla Complex, Mumbai - 400 001. Bandra(E), Mumbai - 400 051 Scrip Code: 532637 Symbol: MANGALAM Sub: Qutcome of the Board Meeting held on Thursday. November 5%, 2026 SEBI Circular CIR / CFD / CMD /4 /2015 dated September 09,2015 Dear Sir / Madam, With respect to the captioned subject and mentioned reference, we are pleased to inform that the Board of Directors of the Company, in their meeting held today i.e., Thursday, November 5th 2026 has inter-alia transacted, considered and approved the following business: 1. The Un-Audited Financial Results (Standalone and Consolidated) along with the Limited Review Report of the Company for the quarter ended September 30, 2026 pursuant to Regulation 33 of the SEBI LODR Regulations. (A copy of the said results, notes thereto and Limited Review Report is annexed hereto and marked as Annexure Pursuant to Regulation 33(3)(d) of the Listing Regulations, we hereby declare that in respect of the Un-Audited Financial Results (Standalone and Consolidated) for the quarter ended September 30, 2026, the statutory Auditors have not expressed any modified opinion(s) in their Limited Review Reports. The Board meeting commenced at 02:30 P.M. and concluded at 5: 30 P.M. We request you to take the same on your records. Thanking You, Yours faithfully, For Mangalam Drugs & Organics Limited Govardhan M. Dhoot Chairman & Managing Director DIN: 01240086 Factory : at Vapi (Gujarat) India ® contactus@mangalamdrugs.com @ http://www.mangalamdrugs.com Mumbai Office: G 69/70, Shagun Arcade, Gen A.K. S N N AND A 6,. CO Vaidya Marg, Malad East, . = 3 Mumbai 400063 CHARTERED ACCOUNTANTS Email: mumbaisnn@gmail.com PH: 91-11-26227853, 41063561, 41450132 Limited Review Report on Unaudited Consolidated Financial Results of Mangalam Drugs and Organics Limited for the Quarter and Half yearly ended on 30" September, 2026 pursuant to Regulation 33 and Regulation 52(4) read with Regulation 63 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10" August 2021 as amended. To the Board of Directors, Mangalam Drugs and Organics Limited 1. We have reviewed the accompanying Statement of unaudited consolidated financial results ("the Statement") of Mangalam Drugs and Organics Limited (hereinafter referred to as "the Parent"), its subsidiary (the Parent and its subsidiary together referred to as "the Group") and its share of the net Loss after tax and total comprehensive income ofi ts subsidiary for the quarter and Half yearly ended 30™ September 2026, being submitted by the Parent pursuant to the requirements of Regulation 33 and Regulation 52(4) read with Regulation 63 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"), as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10™ August 2021, as amended. 2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the requirement of recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 and Regulation 52(4) read with Regulation 63 of the Listing Regulations, as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10* August 2021. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. 4. We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable. 5. The statement includes the results of the Mangalam Laboratories Private Limited af$ which is not a material subsidiary. HO AT: NEW DELHI | BRANCHES: MUMBAI & KOLKATA Mumbai Office: G 69/70, Shagun Arcade, Gen A.K. S.N. NANDA & CO. MVauidmyab aiM .4 0006M3 alad East, CHARTERED ACCOUNTANTS Email: mumbaisnn@gmail.com PH: 91-11-26227853, 41063561, 41450132 6. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 and Regulation 52(4) read with Regulation 63 oft he Listing Regulations, as prescribed in Securities and Exchange Board of India operational circular SEB/HO/DDHS/P/CIR/2021/613 dated 10® August 2021, including the manner in which it is to be disclosed, or that it contains any material misstatement We draw attention to Note No 8 to the Statement, which describes the classification of the Company’s borrowings from two of the three consortium banks as Non-Performing Assets, the demand notice dated 23 September 2026 issued by Bank of Baroda under Section 13(2) of the SARFAESI Act, 2002, and the excess of current liabilities over current assets as at 30 September 2026. The Company is in discussion with the lenders to resolve the debt, the outcome of which is yet to be determined. These conditions indicate that a material uncertainty exists that may cast significant doubt on the Company’s ability to continue as a going concern. Our conclusion is not modified in respect oft his matter. Other Matters 8. We did not review the interim financial results ofa subsidiary included in the Statement, whose interim financial results reflects total revenues (before consolidation adjustments) of Rs.32.10 Lakhs total net loss after tax and total comprehensive income (before consolidation adjustments) of Rs. 8.41 Lakhs for the quarter and Half year ended 30™ September, 2026 and as considered in the Statement. These interim financial results have been reviewed by other auditors whose reports have been furnished to us by the Parent's management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this subsidiary, is based solely on the reports of the other audito [Showing first 8,000 characters — download PDF for full document]